课题基金 / 基金详情

SURFACE-ACTIVE ANTITHROMBOTIC AGENTS FOR PROSTHESES

SURFACE-ACTIVE ANTITHROMBOTIC AGENTS FOR PROSTHESES
用于假体的表面活性抗血栓剂
批准号:
3336774
负责人:
RAMACHANDER GOLLAMUDI
金额:
$18.34万
依托单位国家:
美国
项目类别:
财政年份:
1979
资助国家:
美国
项目状态:
已结题
起止时间:
1979-04-01 至 1995-07-31

项目摘要

项目成果

RAMACHANDER GOLLAMUDI的其他基金

相似基金

相关文献

中文摘要
翻译
该项目旨在开发新的合成化合物,能够 稳定血小板膜。其中一个主要的冲刺是针对 帮助特别易患血栓栓塞症的患者 由于他们的血液暴露在植入的生物材料中 假体装置和体外循环设备。在这个提案中,小说 分子实体将通过三管齐下的方法获得:(I) 由于对映体选择性在药物作用中的重要性,每一个 他们之前的研究中最活跃的3种化合物将是 分解成它的3个立体异构体。个别对映体和 将测试非对映异构体对人体血液的抑制作用 人α-凝血酶、胶原诱导的体外血小板聚集 还有肾上腺素。(2)这3个化合物的外消旋类似物 合成以延长其作用时间,以及(Iii) 疏水性和电子密度将在结构上进行优化 以前未检查过的组件。显示出合理效力的化合物 在初步筛选中,将评估它们在体外的效果,(A) 胞内游离钙([Ca.2+])浓度,(B)关于 血小板第4因子(PF-4)、第3因子(PF-3)和5-羟色胺;(C) 用于体内和小鼠的急性毒性。 与莱斯大学的拉里·V·麦金泰尔博士合作, 将对人体血液的动力学进行研究 胶原蛋白与血栓形成对血小板黏附和血栓生长的影响 HIS平行板流室系统中的生物材料。 将测试一到两种高活性和毒性最低的化合物 狗的体外血小板聚集抑制活性。这个 相同化合物的药代动力学将在小鼠和狗身上进行评估, 和狗的生物利用度。在尿液中发现的代谢物的结构 用高效液相色谱-质谱仪建立。 由于许多生物系统的手性环境,描绘 这些合成化合物的对映体选择性有望达到 发现增强的抗血栓效力,同时可以 登记毒性较小。结构特征的识别 与代谢失活相关会提供最终的线索 设计具有最佳作用时间的高活性分子。 合成化合物的结构特征与其影响的关系 关于血小板反应应允许对人类血液的解释 在化学参数方面的血小板反应模式,和‘好- 调整分子片段以达到最佳活性。
英文摘要
This project is aimed at developing novel synthetic compounds capable of stabilizing platelet membranes. One of the major thrusts is directed at aiding individuals especially predisposed to thromboembolic complicating resulting from their blood's exposure to biomaterials like implanted prosthetic devices and extracorporeal equipment. In this proposal, novel molecular entities will be obtained using a three-pronged approach: (i) because of the importance of enantioselectivity in drug action, each of the 3 most active compounds from their previous investigation will be resolved into its 3 stereoisomers. The individual enantiomers and diastereomers will be tested for their inhibitory effects on human blood platelet aggregation in vitro, induced by human alpha-thrombin, collagen, and epinephrine. (ii) Racemic analogues of the 3 compounds will be synthesized in order to extend their duration of action, and (iii) hydrophbiaity and electron density will be optimized in structural components not previously examined. Compounds showing reasonable potency in preliminary screening will be evaluated for their effects in vitro, (a) on cytosolic ionized calcium ([Ca. 2+]) concentrations, (b) on levels of platelet factor 4 (PF-4), platelet factor 3 (PF-3) and serotonin, and (c) for acute toxicity in vivo, in mice. In cooperation with Dr. Larry V. McIntire, at Rice University, the impact of selected compounds will be studied on the kinetics of human blood platelet adhesion and thrombus growth effected by collagen and biomaterials in his parallel plate flow chamber system. One or two highly active and least toxic compounds will be tested for platelet aggregation inhibitory activity, ex vivo, in dogs. The pharmacokinetics of the same compounds will be evaluated in mice and dogs, and bioavailibility in dogs. Structure of metabolites found in urine will be established using HPLC-MS. Due to the chiral environment of many biological systems, delineation of the enantio-selectivity of these synthetic compounds is expected to uncover increased antithrombotic potency which, at the same time, could register lesser toxicity. Identification of the structural features associated with metabolic inactivation would provide leads to the eventual design of highly active molecules with optimal duration of action. Relating structural features of the synthetic compounds to their influence on thrombocyte response should permit interpretation of human blood platelet response patterns in terms of chemical parameters, and to 'fine- tune' molecular segments toward optimal activity.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
SURFACE-ACTIVE ANTITHROMBOTIC AGENTS FOR PROSTHESES
SURFACE-ACTIVE ANTITHROMBOTIC AGENTS FOR PROSTHESES
SURFACE-ACTIVE ANTITHROMBOTIC AGENTS FOR PROSTHESES
SURFACE-ACTIVE ANTITHROMBOTIC AGENTS FOR PROSTHESES
海外基金